A prospective randomized controlled study on the efficacy and tolerance of two antilymphocytic globulins in the prevention of rejection in first-heart transplant recipients

Transplant International

Volumn 15, Issue 6, 2002, Pages 317-325

  Schnetzler, Bruno ^a,b   Leger, Philippe ^b   Völp, Andreas ^c   Dorent, Richard ^b   Pavie, Alain ^b   Gandjbakhch, Iradj ^b  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^c NONE   (Germany)

Author keywords

Acute rejection; Antilymphocyte globulins; Cardiac transplantation

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN; LYMPHOCYTE ANTIBODY; METHYLPREDNISOLONE; OKT 3; POLYCLONAL ANTISERUM; PREDNISONE; THYMOCYTE ANTIBODY;

ADULT; ARTICLE; BACTERIAL INFECTION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DISEASE SEVERITY; DRUG EFFICACY; DRUG TOLERABILITY; DRUG TOLERANCE; FEMALE; FISHER EXACT TEST; GRAFT REJECTION; GRAFT SURVIVAL; HEART GRAFT; HEART TRANSPLANTATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LYMPHOCYTE COUNT; MALE; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RECIPIENT; SEPSIS;

ADULT; AGED; ANTILYMPHOCYTE SERUM; CYTOMEGALOVIRUS INFECTIONS; FEMALE; GRAFT REJECTION; HEART TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LYMPHOCYTE COUNT; MALE; MIDDLE AGED; ORGAN PRESERVATION; PLATELET COUNT; PROSPECTIVE STUDIES; TISSUE DONORS;

EID: 0036933592     PISSN: 09340874     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1432-2277.2002.tb00171.x     Document Type: Article

References (27)

1. Beniaminovitz A, Itescu S, Lietz K, Donovan M, Burke EM, Groff BD, Edwards N, Mancini DM (2000) Prevention of rejection in cardiac transplantation by blockade of the interleukin-2 receptor with a monoclonal antibody. N Engl J Med 342: 613-619
2. Billingham ME (1982) Diagnosis of cardiac rejection by endomyocardial biopsy. J Heart Transplant 1:25-30
3. Bonnefoy-Berard N, Revillard JP (1996) Mechanisms of immunosuppression induced by antithymocyte globulins and OKT3. J Heart Lung Transplant 15:435-442
4. Bonnefoy-Berard N, Vincent C, Revillard JP (1991) Antibodies against functional leucocyte surface molecules in polyclonal antilymphocyte and antithymocyte globulins. Transplantation 51:669-673
5. Carey JA, Frist WH (1990) Use of polyclonal antilymphocyte preparations for prophylaxis in heart transplantation. J Heart Transplant 9:297-300
6. Costanzo-Nordin MR, O'Sullivan EJ, Johnson MR, Winters GL, Pifarre R, Radvany R, Zucker MJ, Scanlon PJ, Robinson JA (1990) Prospective randomized trial of OKT3 versus horse antithymocyte globulin-based immunosuppressive prophylaxis in heart transplantation. J Heart Transplant 9:306-315
7. Deeb GM, Bolling SF, Steimle CN, Dawe JE, McKay AL, Richardson AM (1991) A randomized prospective comparison of MALG with OKT3 for rescue therapy of acute myocardial rejection. Transplantation 51:180-183
8. Desruennes M, Corcos T, Cabrol A, Gandjbakhch I, Pavie A, Leger P, Eugen M, Bors V, Cabrol C (1988) Doppler echocardiography for the diagnosis of acute cardiac allograft rejection. J Am Coll Cardiol 12:63-70
9. Eisen HJ, Hobbs RE, Davis SF, Laufer G, Mancini DM, Renlund DG, Valantine H, Venture H, Vachiery JL, Bourge RC, Canver CC, Carrier M, Costanzo MR, Copeland J, Dureau G, Frazier OH, Dorent R, Hauptman PJ, Kells C, Master R, Michaud JL, Paradis I, Smith A, Vanhaecke J, Mueller EA et al. (1999) Safety, tolerability and efficacy of cyclosporine microemulsion in heart transplant recipients: a randomized, multicenter, double-blind comparison with the oil-based formulation of cyclosporine - results at six months after transplantation. Transplantation 68:663-671
10. Grant SC, Lamb WR, Yonan N, Hutchinson IV, Brenchley PEC (1995) Antithymocyte globulin preparations after heart transplantation. Cytokine responses in vivo and in vitro. Transplantation 60:684-689
11. Ippoliti G, Rovati B, Graffigna A (1989) Prophylactic use of rabbit ATG vs horse ALG in heart-transplanted patients under Sandimmun (CyA) therapy: clinical and immunological effects. Clin Transplant 3:1-5
12. Kormos RL, Armitage JM, Dummer JS, Miyamoto Y, Griffith BP, Hardesty RL (1990) Optimal perioperative immunosuppression in cardiac transplantation using rabbit antithymocyte globulin. Transplantation 49:306-311
13. Ladowski JS, Dillon T, Schatzlein MH, Peterson AC, Deschner WP, Beatty L, Sullivan M, Scheeringa RH, Clark WR (1993) Prophylaxis of heart transplant rejection with either antithymocyte globulin, Minnesota antilymphocyte globulin, or an OKT3-based protocol. J Cardiovasc Surg 34:135-140
14. Laske A, Gallino A, Schneider J, Bauer EP, Carret T, Pasic M, von Segesser LK, Turina MI (1992) Prophylactic cytolytic therapy in heart transplantation: monoclonal versus polyclonal antibody therapy. J Heart Lung Transplant 11:557-563
15. Laufer G, Laczkowics A, Wollenek G, Schreiner W, Sochor H, Holzinger C, Buchelt M, Fasol R, Wolner E (1989) Impact of low-dose steroids and prophylactic monoclonal versus polyclonal antibodies on acute rejection in cyclosporine- and azathioprine-immunosuppressed cardiac allografts. J Heart Transplant 8:253-261
16. Lower RR, Shumway NE (1960) Studies on orthotopic transplantation of the canine heart. Surg Forum 11:18-20
17. Macdonald PS, Mundy J, Keogh AM, Chang VP, Spratt PM (1993) A prospective randomized study of prophylactic OKT3 versus equine antithymocyte globulin after heart transplantation-increased morbidity with OKT3. Transplantation 55:110-116
18. Menkis AH, Powell AM, Novick RJ, McKenzie FN, Dostuk WJ, Pflugfelder PW, Brown JE, Rochon J, Chow LH, Stiller C (1992) A prospective randomized controlled trial of initial immunosuppression with ALG versus OKT3 in recipients of cardiac allografts. J Heart Lung Transplant 11:569-576
19. Raefsky EP, Gascon P, Gratwohl A, Speck B, Young NS (1986) Biological and immunological characterization of ATG and ALG. Blood 68:712-719
20. Reichart B, Meiser B, Vigano M, Rinaldi M, Yacoub M, Banner NR, Gandjbakhch I, Dorent R, Hetzer R, Hummel M (2001) European multicenter tacrolimus heart pilot study: three years follow-up. J Heart Lung Transplant 20:249-250
21. Renlund DG, O'Connell JB, Bristow MR (1989) Early rejection prophylaxis in heart transplantation: is cytolytic therapy necessary? J Heart Transplant 8:191-193
22. Schnetzler B, Pavie A, Dorent R, Camproux AC, Leger P, Delcourt A, Gandjbakhch I (1998) Heart retransplantation. A 23-year single-centre clinical experience. Ann Thorac Surg 65:978-983
23. Smith AG, O'Reilly RJ, Hansen JA, Martin PJ (1985) Specific antibody-blocking activities in antilymphocyte globulins as correlates of efficacy for the treatment of aplastic anemia. Blood 66:721-723
24. Soulillou JP, Cantarovich D, Le Mauff B, Giral M, Robillard N, Hourmant M, Hirn M, Jacques Y (1990) Randomized controlled trial of a monoclonal antibody against the interleukin-2 receptor (33B3.1) as compared with rabbit antithymocyte globulin for prophylaxis against rejection of renal allografts. N Engl J Med 322:1175-1182
25. Swinnen LF, Costanzo-Nordin M, Fisher SG, O'Sullivan EJ, Hohnson MR, Heroux AL, Dizikes GJ, Pifarre R, Fisher RI (1990) Increased incidence of lymphoproliferative disorder after immunosuppression with the monoclonal antibody OKT3 in cardiac-transplant recipients. N Engl J Med 323:1723-1728
26. Vincenti F, Kirkman R, Light S, Bumgardner G, Pescovitz M, Halloran Neylan J, Wilkinson A, Ekberg H, Gaston R, Backman L, Burdick J (1998) Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. N Engl J Med 338:161-165
27. Wagner FM, Reichenspurner H, Uberfuhr P, Kur F, Kaulbach HG, Meiser BM, Ziegler U, Reichart B (1994) How successful is OKT3 rescue therapy for steroid-resistant acute rejection episodes after heart transplantation? J Heart Lung Transplant 13:438-443